Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA; Department of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA; Department of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
Cell Metab. 2015 Oct 6;22(4):541-3. doi: 10.1016/j.cmet.2015.09.019.
While mesenchymal stem cells (MSCs) are rapidly cleared from the body following systemic transplantation, their therapeutic benefits typically persist. In this issue, Liu et al. (2015) reveal that the ability of transplanted MSCs to alleviate osteoporosis in systemic lupus erythematosus is maintained through epigenetic changes conferred by secretory action of the MSCs.
虽然间充质干细胞(MSCs)在全身移植后会迅速从体内清除,但它们的治疗益处通常会持续存在。在本期杂志中,Liu 等人(2015 年)揭示了移植的 MSCs 通过其分泌作用赋予的表观遗传变化,从而维持其缓解系统性红斑狼疮中骨质疏松症的能力。